US Patent 9,504,691: Finafloxacin Suspension Claims, Expiration, Litigation and Generic Risk

US Patent 9,504,691 protects a narrowly defined finafloxacin suspension platform rather than finafloxacin as a molecule. Its principal coverage requires finafloxacin free base Form A, a magnesium-based solubilizer, hydroxyethylcellulose, defined concentration ranges, pH 5.8 to 6.2, and physical uniformity for more than eight hours. The patent also covers dexamethasone combinations, treatment of otic and related infections, and a milling-and-heating process for producing Form A.

The patent is commercially relevant to Alcon’s Xtoro, a 0.3% finafloxacin otic suspension approved by the FDA for acute otitis externa. The strongest infringement risk would arise from a generic product that copies both the formulation architecture and the Form A manufacturing process. A product using a different crystal form, polymer, magnesium concentration, pH, or manufacturing route could avoid literal infringement, although the doctrine of equivalents and related formulation patents would remain relevant.

What does US Patent 9,504,691 cover?

US 9,504,691 is a formulation, method-of-use, and manufacturing patent directed to topical finafloxacin suspensions. The patent does not broadly claim every finafloxacin product.

Claim group	Subject matter	Commercial relevance
Claim 1	Finafloxacin Form A suspension with magnesium salt, hydroxyethylcellulose, defined pH, concentration, and stability	Core formulation claim
Claims 2-3	Suspended-to-solubilized ratio and magnesium chloride concentration	Narrows the core composition
Claims 4-6	Addition of an anti-inflammatory agent, particularly dexamethasone	Combination-product coverage
Claims 7-8	Treatment of ophthalmic, otic, or nasal infections; specifically acute otitis externa and otitis media with tympanostomy tubes	Method-of-use coverage
Claims 9-12	Milling, slurry formation, heating, Form A production, and dexamethasone-containing processing	Manufacturing-process coverage

The claims use “comprising,” which generally makes them open-ended. A product can contain additional excipients and still fall within the claims if it satisfies every required limitation.

How narrow is claim 1 of US 9,504,691?

Claim 1 is narrow because it combines multiple structural, compositional, physicochemical, and performance limitations.

A literal infringement analysis would generally examine whether the accused product has all of the following:

A topical suspension composition.
Finafloxacin as the active ingredient.
Finafloxacin free base Form A.
A magnesium salt as the solubilizer.
Magnesium salt at 0.98 to 4.9 mM.
Hydroxyethylcellulose at 0.1 to 0.3% weight/volume.
Finafloxacin at 0.15 to 2.0% weight/volume.
pH between 5.8 and 6.2.
Substantial uniformity for more than eight hours at 25°C.

The claim is stronger against products that use the same Form A material and the same excipient design. It is weaker against a formulation that substitutes another solubilizer, uses a different suspending polymer, changes the pH outside the stated range, or employs a different polymorph.

The “substantial uniformity” limitation may create a factual dispute. The patent claim does not establish a single quantitative test in the text supplied. In litigation, the parties would likely contest the meaning of substantial uniformity, the sampling protocol, the acceptance criterion, and whether the eight-hour test must be performed at 25°C under specified storage and agitation conditions.

What formulations are protected by US 9,504,691?

The patent protects a suspension design using a low concentration of magnesium salt and hydroxyethylcellulose to maintain finafloxacin in a physically stable, doseable form.

Finafloxacin concentration

Claim 1 covers finafloxacin at 0.15 to 2.0% weight/volume. Xtoro contains finafloxacin 0.3% weight/volume, placing the marketed product within this range according to its FDA labeling.[2]

Magnesium salt

Claim 1 covers a magnesium salt at 0.98 to 4.9 mM. Claim 3 narrows the solubilizer to magnesium chloride at 0.05 to 0.07% weight/volume.

The numerical relationship between these limitations requires careful claim construction. Anhydrous magnesium chloride at 0.05 to 0.07% weight/volume corresponds approximately to 5.25 to 7.35 mM, which is above the 0.98 to 4.9 mM range in claim 1. The calculation changes with the hydrate form and molecular-weight basis, but claim 3 should not be assumed to fall automatically within claim 1 without resolving the relevant magnesium chloride form and concentration convention.

This apparent range tension is a potential validity and infringement issue. It does not automatically invalidate claim 3, because dependent-claim interpretation and the patent’s specification may clarify the intended formulation basis. It does create avoidable litigation risk.

Hydroxyethylcellulose

Claim 1 requires hydroxyethylcellulose at 0.1 to 0.3% weight/volume. A generic using carboxymethylcellulose, hypromellose, polyvinyl alcohol, or another suspending agent would not literally satisfy this limitation.

pH

The pH range of 5.8 to 6.2 is tight. A product at pH 5.7 or 6.3 could avoid literal infringement of claim 1, subject to testing variability, claim-construction principles, and equivalents analysis.

Dexamethasone combination

Claims 4 through 6 cover a finafloxacin suspension containing an anti-inflammatory agent. Claim 5 identifies dexamethasone, and claim 6 covers dexamethasone at 0.05 to 1.0% weight/volume.

These claims are relevant to combination products but are not necessary to infringe claim 1. A finafloxacin-only product could infringe claim 1 without infringing claims 4 through 6.

What manufacturing methods are protected?

Claims 9 through 12 protect a wet-milling and heating process.

The process requires:

Finafloxacin free base.
A milling agent.
Milling beads.
Water.
Formation of an aqueous slurry.
Heating the slurry to form finafloxacin free base Form A.

Claims 11 and 12 add one or more anti-inflammatory agents, with dexamethasone specified in claim 12.

The manufacturing claims can create a separate infringement route even where a finished product is difficult to characterize. A generic manufacturer may avoid direct process infringement by using a different crystallization process, purchasing Form A from a third party, using a different milling technology, or producing the suspension without the claimed heating step. The commercial risk then depends on process evidence, discovery, supplier records, and whether the process produces the same claimed Form A material.

Claim 9 appears to depend on claim 1 while adding process limitations. Claim 10 is written as a separate independent process claim but repeats much of the process language in claim 9. That structure may affect claim differentiation and the scope of the two process claims.

When does US Patent 9,504,691 expire?

The patent issued on November 29, 2016.[1] Its ordinary US patent term is calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension.

Public Orange Book information should control the operative listed expiration date for FDA-regulated generic-entry analysis. Patent term cannot be determined solely from the issue date. For business planning, the relevant date is the expiration date listed for the patent in the current FDA Orange Book, not an estimate based only on the twenty-year rule.[3]

The patent’s practical exclusivity period also reflects FDA regulatory exclusivity:

Milestone	Date or status
Xtoro NDA approval	December 17, 2014
FDA product	Finafloxacin otic suspension, 0.3%
Approval indication	Acute otitis externa
New-drug regulatory exclusivity	Three-year exclusivity associated with approval of a product supported by new clinical investigations
Patent exclusivity	Governed by the listed US patent term and any term adjustment or extension
Biosimilar exclusivity	Not applicable

The FDA label identifies Xtoro as a topical otic suspension containing finafloxacin 0.3%.[2]

What is the Orange Book status of finafloxacin and Xtoro?

Xtoro is an FDA-approved small-molecule drug product, not a biologic. Its generic pathway is an abbreviated new drug application, or ANDA, rather than a biosimilar application.

The Orange Book is the primary source for:

Listed patents associated with the approved NDA.
Patent expiration dates.
FDA use codes for method-of-use patents.
The regulatory basis for a Paragraph IV certification.
Whether a patent is listed against the relevant dosage form and route.

A listed method-of-use patent may not block every generic use. Its effect depends on the use code and the proposed labeling of the ANDA. A generic applicant can seek a section viii statement for a use that is carved out, where permitted, rather than certify that the method patent is invalid or not infringed.

What Paragraph IV challenges could target US 9,504,691?

A finafloxacin ANDA applicant could make a Paragraph IV certification alleging that the patent is invalid, unenforceable, or will not be infringed. The most plausible technical positions would involve:

Noninfringement

A proposed generic could attempt to avoid claim 1 by:

Using a non-magnesium solubilizer.
Replacing hydroxyethylcellulose.
Selecting a different finafloxacin polymorph.
Adjusting pH outside 5.8 to 6.2.
Using a concentration outside the claimed ranges.
Demonstrating that the product does not maintain the claimed uniformity for more than eight hours.
Using a different manufacturing process.

Invalidity

Potential invalidity theories would depend on the prior-art record and prosecution history. They could include:

Anticipation by an earlier finafloxacin suspension disclosure.
Obviousness based on known finafloxacin formulations, magnesium salts, cellulose suspending agents, and pH optimization.
Lack of written description for the full combination of narrow numerical ranges.
Enablement challenges to the claimed stability and uniformity result.
Indefiniteness concerning “substantial uniformity” or the relationship between magnesium concentration units.

The Form A limitation may help the patent against generic formulations but also makes the claim dependent on reliable polymorph identification and reproducible analytical methods.

What patent litigation and settlement agreements affect Xtoro?

A publicly reliable assessment must distinguish between patent records, FDA listings, and court dockets. The existence of an Orange Book listing does not prove that a Paragraph IV suit has been filed. A definitive litigation analysis requires the relevant district-court docket and any associated appellate proceedings.

For Xtoro, the central litigation trigger would be an ANDA notification containing a Paragraph IV certification against an Orange Book-listed finafloxacin patent. If the NDA holder files suit within 45 days, FDA approval of the ANDA may be subject to a statutory 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court action.[4]

No biosimilar litigation applies because finafloxacin is a small molecule. Any future challenge would proceed through the ANDA and Hatch-Waxman framework.

How strong is the patent estate for finafloxacin?

The estate is strongest when viewed as a layered formulation and manufacturing portfolio:

Layer	Protection	Relative strength
Active molecule	Finafloxacin compound patents, where still enforceable	Potentially limited by earlier priority and term
Formulation	Form A, magnesium salt, hydroxyethylcellulose, pH, concentration, uniformity	Strong against close copies; narrow claim perimeter
Combination	Dexamethasone-containing suspension	Relevant only to combination products
Method of use	Otic, ophthalmic, and nasal infection treatment	Dependent on FDA labeling and use-code scope
Manufacturing	Wet milling and heating to produce Form A	Strong if the accused process is discoverable and copied
Regulatory	NDA exclusivity and Orange Book listing	Delays ANDA approval but does not extend patent validity

US 9,504,691 is not a broad barrier to all finafloxacin products. It is a targeted barrier to a specific suspension technology. Its commercial value depends on whether a generic can develop a clinically acceptable product without using the claimed excipient system or Form A process.

How does Xtoro compare with generic launch scenarios?

Generic strategy	Likely patent exposure	Commercial assessment
Copy Xtoro’s 0.3% formulation	High risk under claim 1	Direct Paragraph IV challenge likely
Use another suspending polymer	Lower literal risk under claim 1	Requires formulation and clinical comparability work
Use a different polymorph	Lower risk if analytically distinct	Must establish comparable safety, efficacy, and stability
Change pH modestly	Potentially lower literal risk	May affect tolerability, solubility, and performance
Omit magnesium salt	Avoids a central limitation	May compromise finafloxacin suspension behavior
Use a different manufacturing route	Avoids process claims if independently developed	Product claims remain separately relevant
Market finafloxacin with dexamethasone	Additional combination-claim exposure	May trigger claims 4 through 6
Seek a carved-out indication	May avoid some method claims	Depends on the Orange Book use code and labeling

What is the revenue exposure from US Patent 9,504,691?

Alcon does not generally report Xtoro revenue as a separate material product line in its public financial reporting. Product-level revenue exposure therefore cannot be calculated reliably from company filings alone.

The commercial value of the patent is more closely tied to:

Duration of branded otic exclusivity.
The number and timing of ANDA filers.
The ability of generics to design around Form A and the excipient system.
The size of the acute otitis externa market.
The absence or presence of competing branded fluoroquinolone otic products.
Whether a generic can obtain approval with a narrow or carved-out label.

Because the product is an otic anti-infective rather than a high-volume systemic medicine, generic entry could compress price and share rapidly once FDA approval is available, even if the absolute revenue base is modest.

Key takeaways

US 9,504,691 is a narrow formulation and process patent, not a broad finafloxacin molecule patent.
Claim 1 requires Form A finafloxacin, a magnesium salt, hydroxyethylcellulose, tight concentration ranges, pH 5.8 to 6.2, and more than eight hours of uniformity.
Claims 4 through 6 cover finafloxacin-dexamethasone combinations.
Claims 9 through 12 protect wet milling and heating steps used to produce Form A.
Xtoro’s 0.3% finafloxacin otic suspension falls within the principal active-concentration range.
The magnesium chloride concentration in claim 3 raises a numerical interpretation issue when compared with claim 1.
Generic entry would most likely involve a Paragraph IV challenge, a design-around, or both.
Biosimilar risk does not apply.
The current FDA Orange Book entry and patent docket determine the operative expiration and litigation position.

FAQs

Does US 9,504,691 cover finafloxacin eye drops?

Claim 1 covers a topical suspension, and claims 7 and 8 refer to ophthalmic, otic, or nasal infections. The patent therefore has language broad enough to reach certain ophthalmic suspensions, but infringement depends on every formulation limitation and the relevant product labeling.

Can a generic avoid the patent by using finafloxacin hydrochloride instead of Form A free base?

A product using a different chemical form would have a strong noninfringement position against the Form A limitation, assuming the product does not contain Form A as manufactured or during storage. Analytical characterization and conversion behavior would be material.

Does claim 3 independently protect magnesium chloride at 0.05 to 0.07%?

Claim 3 is written as dependent on claim 1, so it incorporates claim 1’s limitations. The apparent difference between the molar range in claim 1 and the weight/volume range in claim 3 requires analysis of the patent specification, salt hydration state, and claim construction.

Is dexamethasone required to infringe the main Xtoro formulation claim?

No. Dexamethasone is not required by claim 1. It is introduced through claims 4 through 6. A finafloxacin-only suspension can potentially infringe claim 1 without infringing the dexamethasone claims.

What is the most important design-around for a finafloxacin generic?

The most direct design-around is to avoid the combination of Form A, magnesium salt, hydroxyethylcellulose, and the claimed pH and concentration ranges. A separate manufacturing route can also reduce exposure to claims 9 through 12, but it does not by itself avoid the composition claims.

References

United States Patent and Trademark Office. (2016). United States Patent No. 9,504,691, Finafloxacin compositions and methods of use thereof.
U.S. Food and Drug Administration. (2014). Xtoro (finafloxacin ophthalmic suspension) prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Code, 21 U.S.C. § 355(j). (n.d.). Abbreviated applications and patent certifications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fonseca Biosciences	XTORO	finafloxacin	SUSPENSION/DROPS;OTIC	206307-001	Dec 17, 2014		RX	Yes	Yes	9,504,691	⤷ Start Trial	Y			TREATMENT OF ACUTE OTITIS EXTERNA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	093813	⤷ Start Trial
Australia	2013356488	⤷ Start Trial
Brazil	112015010927	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,504,691

Which drugs does patent 9,504,691 protect, and when does it expire?

Summary for Patent: 9,504,691